142 related articles for article (PubMed ID: 36564175)
1. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
van Kempen ZLE; Stalman EW; Steenhuis M; Kummer LYL; van Dam KPJ; Wilbrink MF; Ten Brinke A; van Ham SM; Kuijpers T; Rispens T; Eftimov F; Wieske L; Killestein J;
J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):280-283. PubMed ID: 36564175
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
5. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Sand IK; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
medRxiv; 2022 Jun; ():. PubMed ID: 35734083
[TBL] [Abstract][Full Text] [Related]
8. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Woopen C; Konofalska U; Akgün K; Ziemssen T
Front Immunol; 2022; 13():897748. PubMed ID: 35958567
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Klineova S; Farber RS; DeAngelis T; Leung T; Smith T; Blanck R; Zhovtis-Ryerson L; Harel A
Mult Scler; 2023 Jul; 29(8):990-1000. PubMed ID: 37431628
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.
Bigaut K; Kremer L; Fleury M; Lanotte L; Collongues N; de Seze J
Rev Neurol (Paris); 2021 Dec; 177(10):1237-1240. PubMed ID: 34172292
[TBL] [Abstract][Full Text] [Related]
11. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP; Schiavetti I; Inglese M; Carmisciano L; Laroni A; Lapucci C; Visconti V; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Cocco E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Pizzorno M; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2022 Jun; 80():104042. PubMed ID: 35526306
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
van Kempen ZL; van Dam KP; Keijser JB; Stalman EW; Kummer LY; Strijbis EM; Steenhuis M; Ten Brinke A; van Ham SM; Kuijpers T; Rispens T; Eftimov F; Wieske L; Killestein J
Mult Scler; 2024 Mar; 30(3):443-447. PubMed ID: 37942812
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study.
Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA
Front Immunol; 2023; 14():1194671. PubMed ID: 37449202
[TBL] [Abstract][Full Text] [Related]
15. Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
Novak F; Bajwa HM; Coia JE; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Hvidt MVM; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
J Neurol Neurosurg Psychiatry; 2023 Nov; 94(11):934-937. PubMed ID: 37185261
[TBL] [Abstract][Full Text] [Related]
16. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
17. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Zabalza A; Arrambide G; Otero-Romero S; Pappolla A; Tagliani P; López-Maza S; Cárdenas-Robledo S; Esperalba J; Fernández-Naval C; Martínez-Gallo M; Castillo M; Bonastre M; Resina-Salles M; Bertran J; Rodriguez-Barranco M; Carbonell-Mirabent P; Gonzalez M; Merchan M; Quiroga-Varela A; Miguela A; Gómez I; Álvarez G; Robles R; Perez Del Campo D; Queralt X; Soler MJ; Agraz I; Martinez-Valle F; Rodríguez-Acevedo B; Midaglia L; Vidal-Jordana Á; Cobo-Calvo Á; Tur C; Galan I; Castillo J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Ramió-Torrentà L; Tintoré M; Montalban X
Mult Scler; 2022 Jun; 28(7):1138-1145. PubMed ID: 35475363
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
Yeo T; Siew RWE; Gulam MY; Tye JSN; Aw AYY; Sivalingam T; Peng X; Yong KP; Saffari SE; Chao Y; Tan K
J Neurol; 2023 Jun; 270(6):2817-2825. PubMed ID: 37027019
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.
Otto C; Schwarz T; Jeworowski LM; Schmidt ML; Walper F; Pache F; Schindler P; Niederschweiberer M; Krumbholz A; Rose R; Drosten C; Ruprecht K; Corman VM
Mult Scler; 2023 Jun; 29(7):884-888. PubMed ID: 36974938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
